Advances in Inflammatory Bowel Diseases (AIBD) 2019 Conference

Thiopurine immunomodulators still represent a potentially inexpensive and effective therapy for inflammatory bowel disease (IBD) maintenance even in the advent of biologics, according to a leading gastroenterologist.

Neither sleep quality nor step count had a bearing on length of hospital stay (LOS) following bowel surgery in patients with inflammatory bowel disease (IBD), according to researchers at the recent AIBD 2019 Meeting.

Not one diet is good enough to support treatment of Crohn’s disease (CD) or ulcerative colitis (UC), says an expert at the AIBD 2019 meeting.

Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.

Unusual involvement of the eyes with atypical presentations may occur in patients with inflammatory bowel diseases (IBD) on antitumour necrosis factor (anti-TNF) therapy, according to a recent study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).

Use of adalimumab or infliximab in biologic-naïve patients with inflammatory bowel disease (IBD) delivers comparable rates of corticosteroid-free remission, as shown by a study presented at the Advances in Inflammatory Bowel Disease (AIBD) Conference 2019.

In patients with ulcerative colitis (UC), changes in histologic and endoscopic scores appear to be weakly to moderately predictive of each other, according to an analysis of the HICKORY study presented at the 2019 Advances in Inflammatory Bowel Diseases Annual Meeting (AIBD 2019).

Most patients with moderately to severely active ulcerative colitis and Crohn’s disease on vedolizumab persist with their treatment for up to 5 years, according to a posthoc analysis of the phase III GEMINI long-term safety (LTS) study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting.

The use of oral liposomal iron in the treatment of mild anaemia in inflammatory bowel disease (IBD) patients appears to be effective, producing improvements in haemoglobin levels and quality of life with parallel reductions in fatigue, according to a study presented at the Advances in Inflammatory Bowel Diseases (AIBD) 2019 Annual Meeting_.